Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

Journal of Hematology & Oncology

Ioannis P. Trougakos¹  Aimilia D. Sklirou¹  Eleni-Dimitra Papanagnou¹  Konstantinos Koutsoukos²  Meletios-Athanasios Dimopoulos²  Evangelos Terpos²  Christos Markellos²  Alexandros Briasoulis²  Flora Zagouri²  Michalis Liontos² 

[1] Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece;Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Avenue, 11528, Athens, Greece;

关键词: SARS-CoV-2;    Vaccination;    Cancer;    Immune checkpoint inhibitors;    BNT162b2;    AZD1222;   

DOI  :  10.1186/s13045-021-01099-x

来源: Springer

【 摘 要 】

Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has initiated a study evaluating safety and efficacy of SARS-CoV-2 vaccination in patients with solid and hematological malignancies under several systemic therapies. The initial results of the cohort of 59 patients receiving Immune Checkpoint Inhibitors are presented here. Despite no new safety issues have been noticed, the levels of SARS-CoV-2 neutralizing antibodies are significantly lower in comparison to matched healthy volunteers up to day 22 post the first dose. These results should be taken into consideration for the patients under treatment.

【 授权许可】

CC BY